Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
Go back to Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer| RITE AID CORPORATION (NYSE: RAD) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $8.30 | |||
| Open | $11.16 | 52 Week Low | $6.33 | |||
| Day High | $0.65 | P/E | 1.91 | |||
| Day Low | $0.65 | EPS | $0.34 | |||
| Volume | 63,391 | |||||
| (NASDAQ: RADX) | Delayed: 4.31 -0.14 (3.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.45 | 52 Week High | $ | |||
| Open | $4.36 | 52 Week Low | $ | |||
| Day High | $4.44 | P/E | N/A | |||
| Day Low | $4.30 | EPS | $ | |||
| Volume | 12,382 | |||||
